Literature DB >> 20690664

Serum and urinary metabonomic study of human osteosarcoma.

Zhiyu Zhang1, Yunping Qiu, Yingqi Hua, Yihuang Wang, Tianlu Chen, Aihua Zhao, Yi Chi, Li Pan, Shuo Hu, Jian Li, Chengwei Yang, Guodong Li, Wei Sun, Zhengdong Cai, Wei Jia.   

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor found in children. Currently, researchers have focused on protein and gene levels, while the associated metabolic variations have been poorly understood. In this study, we used a gas chromatography mass spectrometry approach and profiled small-molecule metabolites in serum and urine of 24 OS patients, 19 benign bone tumor patients, and 32 healthy controls, to determine whether there are significant alterations associated with carcinogenesis. The metabonomic results demonstrate clear intergroup separations between healthy control subjects and bone tumor patients in the orthogonal partial least-squares-discriminant analysis (OPLS-DA) models. Differential metabolites identified from the metabonomic analysis suggest a disrupted energy metabolism in OS patients, as characterized by significantly down-regulated TCA cycle and glycolysis, down-regulated lipid metabolism, dysregulated sugar levels, and up-regulated amino acid metabolism. Additionally, an increased activity of glutathione metabolism, and increased polyamine metabolism also contributed to a characteristic metabolic signature of OS patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690664     DOI: 10.1021/pr100480r

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  15 in total

Review 1.  Review of mass spectrometry-based metabolomics in cancer research.

Authors:  David B Liesenfeld; Nina Habermann; Robert W Owen; Augustin Scalbert; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-04       Impact factor: 4.254

Review 2.  Novel methodologies in analysis of small molecule biomarkers and living cells.

Authors:  Yinan Chen; Zhenggang Zhu; Yingyan Yu
Journal:  Tumour Biol       Date:  2014-08-14

Review 3.  Application of metabolomics in sarcoma: From biomarkers to therapeutic targets.

Authors:  Li Min; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Crit Rev Oncol Hematol       Date:  2017-05-13       Impact factor: 6.312

4.  Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells.

Authors:  Kai Chen; Chunyan Zhu; Ming Cai; Dong Fu; Biao Cheng; Zhengdong Cai; Guodong Li; Jilong Liu
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-12       Impact factor: 4.553

Review 5.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

6.  Metabolomics uncovers a link between inositol metabolism and osteosarcoma metastasis.

Authors:  Ling Ren; Ellen S Hong; Arnulfo Mendoza; Sameer Issaq; Christine Tran Hoang; Michael Lizardo; Amy LeBlanc; Chand Khanna
Journal:  Oncotarget       Date:  2017-06-13

Review 7.  Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma.

Authors:  Francesco R Evola; Luciano Costarella; Vito Pavone; Giuseppe Caff; Luca Cannavò; Andrea Sessa; Sergio Avondo; Giuseppe Sessa
Journal:  Front Pharmacol       Date:  2017-04-07       Impact factor: 5.810

8.  Plasma Metabolomics Analysis Based on GC-MS in Infertile Males with Kidney-Yang Deficiency Syndrome.

Authors:  Piao Zheng; Yun Wang; Hongmei Lu; Xinyi Zhou; Tao Tang; Rong Fan; Chunhu Zhang; Hanjin Cui; Yang Wang; Jiekun Luo
Journal:  Evid Based Complement Alternat Med       Date:  2017-09-25       Impact factor: 2.629

9.  Untargeted LC-MS/MS analysis reveals metabolomics feature of osteosarcoma stem cell response to methotrexate.

Authors:  Feng Wang; Zhiyu Zhang; Qin Li; Tao Yu; Chengbin Ma
Journal:  Cancer Cell Int       Date:  2020-06-24       Impact factor: 5.722

10.  Metabonomic strategy to the evaluation of chinese medicine compound danshen dripping pills interfering myocardial ischemia in rats.

Authors:  Xue Xin; Haimiao Zou; Ningning Zheng; Xinchun Xu; Yinmin Liu; Xiaoxian Wang; Hongbing Wu; Lina Lu; Jing Su; Mingfeng Qiu; Xiaoyan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.